Interactive tool

Weight Loss Journey Estimator

A visual projection of what GLP-1 therapy typically looks like over ~68 weeks, based on mean total body weight loss reported in STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide). Outcomes vary by individual.

Your inputs
Medication
Activity level
Estimated outcome
Expected loss in ~68 weeks
35.2 lb
16.0% of body weight
Projected weight
184.8 lb
Goal beyond typical mean — habits & dose matter.

Based on mean total body weight loss in STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide). Individual outcomes vary widely.

Expected phases
  1. Week 4Titration

    Lowest dose; appetite begins to shift. Expect 1–2% drop.

  2. Week 12Early loss

    Steady weekly loss. Side effects typically peak then fade.

  3. Week 24Mid-cycle

    Loss slows but compounds. Body composition shifts visibly.

  4. Week 40Approaching plateau

    Weekly loss thins out. Habits and protein matter most.

  5. Week 68New setpoint

    Mean clinical-trial endpoint. Maintenance phase begins.

Plateaus are normal

Most people stall by month 6–9. The trajectory typically resumes with steady protein intake, resistance training, and time at a stable dose.

Non-scale victories

Lower A1C, smaller waist, better sleep, reduced food noise, and improved energy often arrive before the scale catches up.

Estimator is educational only. It is not a clinical prediction and does not replace guidance from your prescriber.